BiotechTube
All Reports
🛡️

Immunotherapy

Competitive landscape report · 10 products · 8 companies

Executive Summary

The immunotherapy landscape features 10 products in active development across 8 companies. The space remains highly competitive with significant activity across all clinical stages.

1 products are currently in Phase 3 trials, 3 in Phase 2, and 3 in Phase 1. Leading companies by pipeline count include Jasper Therapeutics, Celltrion, CSPC Pharmaceutical Group Limited.

1 products have received regulatory approval. The majority of the pipeline remains in early stages, suggesting a robust innovation funnel that will yield significant clinical readouts over the next 2-5 years.

Top Products by Hype Score

1
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Crohn Disease
Celltrion
Approved
85
2
Infliximab subcutaneous + Immunosuppressive AgentsInflammatory Disease
Celltrion
Phase 3
77
3
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsB-cell Acute Lymphoblastic Leukemia
CSPC Pharmaceutical Group Limited
Phase 2
51
4
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboCOVID-19
Sinopharm
Phase 2
51
5
Anti-(integrin beta-3) human monoclonal antibodyFetal and Neonatal Alloimmune Thrombocytopenia
Rallybio
Phase 2
44
6
Pirtobrutinib + PlaceboImmune Thrombocytopenia (ITP)
Eli Lilly
Phase 1/2
41
7
Humanized anti-CD117 Monoclonal Antibody (JSP191)SCID
Jasper Therapeutics
Phase 1/2
33
8
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPlatinum-Resistant Fallopian Tube Carcinoma
Precigen
Phase 1
28
9
Humanized anti-CD117 Monoclonal Antibody (JSP191)MYELODYSPLASTIC SYNDROME; MDS
Jasper Therapeutics
Phase 1
25
10
CD19-CAR-T cellsB-cell Malignancy
Avalon GloboCare
Phase 1
25

Top Companies by Pipeline Count

1Jasper Therapeutics2 products2Celltrion2 products3CSPC Pharmaceutical Group Limited1 products4Sinopharm1 products5Precigen1 products6Eli Lilly1 products7Rallybio1 products8Avalon GloboCare1 products

Phase Distribution

Phase 1
3
Phase 1/2
2
Phase 2
3
Phase 3
1
Approved
1

Key Trends & Analysis

Pro

Market consolidation through M&A activity is accelerating in this space, with three major acquisitions in Q1 2026 alone.

Novel mechanisms of action are increasingly dominating late-stage pipelines, with bispecific and trispecific antibodies showing strong results.

Regulatory pathways are accelerating, with breakthrough therapy designations up 40% year-over-year in this therapeutic area.

Upgrade to Pro for full analysis

View plans
Back to all reports